Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite ...

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Dry through Wednesday; Wintry Mess for Thursday China hits back with levies on US products after Trump's tariffs take effect ...